All News

More than ever, patients are turning to OTC products to treat conditions like allergies, arthritis, coughs, colds, migraines, and gastrointestinal issues.

Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.

STRONG-HF aimed to study whether rapid-dose escalation of guideline-directed heart failure medications was more beneficial than usual care.

Ambulatory care pharmacy residents play a major role in increasing both patient awareness about recommended vaccination and vaccination rates.

Even with technological advancements, provider involvement and oversight remain essential.

Investigators of the study aimed to determine whether the analytical performance specifications of 24,25(OH)2D could be generated.

As the OTC market has grown, Pharmacy Times has responded by adding new health sections and new OTC products to the survey.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

Acne, atopic dermatitis, rosacea, urticaria, and sunburn present differently and require specific management.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.

Randomized clinical trials still showed that microbiota restoration is significantly more effective than antibiotics for recurrent Clostridioides difficile infection.

Study highlights the importance of interprofessional decision-making between pharmacists and emergency department medical officers.

There are 8 million cancer survivors who may have limitations in their daily functional ability.

The CDC has recommended a follow-up nucleic acid amplification test to be used for patients clinically suspected to have influenza, despite a negative POC test.

April Gill, chief commercial officer at Tabula Rasa HealthCare, discusses how to identify underserved patients and address social determinants of health.

Investigators from the Barts Cancer Institute discovered that AMP-activated protein kinase is an essential sensor for tumor dissemination.

The estimated cost burden of schizophrenia is more than $150 billion, consisting of direct treatment cost and lost productivity.

People with less severe symptoms of insomnia still had a 16% increased risk of stroke compared to people with no symptoms.

Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.

Positive data from the phase 3 A DUE study demonstrated that the investigational combination therapy of macitentan 10 mg and tadalafil 40 in a single tablet improved pulmonary hemodynamics compared to the same drugs as monotherapies.